Liquidia to pay $380.7M to United Therapeutics, resolving all litigation and keeping YUTREPIA in PAH

Liquidia Corp

Settlement resolves all six lawsuits with UTHR, including U.S. Patent 11,826,327, trade secret and antitrust cases; Liquidia will not appeal Delaware ruling.
Liquidia will pay UTHR net $175.0M within 30 business days plus $145.4M in two $72.7M installments due Jan 31 and Apr 30, 2027.
Liquidia will remove PH-ILD indication from YUTREPIA label and cease promotion; YUTREPIA remains marketed for PAH.
Q3 2026 preliminary YUTREPIA net sales were $222.7M; cash and equivalents were $396.1M as of Sept 30, 2026.
Liquidia also pays $60.3M to Sandoz, Henderson and PBM to settle RareGen antitrust interests; HCR minimum cash covenant rises to $45.0M.

item 1.01 item 1.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.